Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Genetic Modifiers of Eukaryotic Translation Termination

FY 2018-19

Summary
Genes function as instruction manuals for making proteins, encoding transcripts that are ultimately decoded to make proteins that perform a vast array of functions in our cells. During the translation of these transcripts, certain sequences (termed stop or termination codons) signal to the cell machinery that the full-length protein has been synthesized and it is time to stop. Sometimes, however, this process can be disrupted by mutations that introduce premature termination codons (PTCs), resulting in the synthesis of truncated proteins. These mutations have been linked to many genetic diseases, such as Duchenne muscular dystrophy, cystic fibrosis, and a plethora of cancer syndromes. Therefore, developing strategies to “mask” stop codon recognition and re-initiate production of full-length proteins in order to restore, at the very least, partial protein function could have significant therapeutic applications. In fact, certain drugs (eg. aminoglycosides) already do this and have been shown to reduce disease severity in cancer cells, but they only do so at very high concentrations that are eventually toxic. Another drug (Ataluren) that promotes readthrough of PTCs is already being used in Europe to treat Duchenne muscular dystrophy patients, demonstrating the feasibility of suppressing stop codons as a form of therapy. In this project, we hope to better understand the mechanisms behind translation termination and how fidelity is maintained. To achieve this, we will design genetic screens using CRISPR technology to find suppressors of translation termination. Should we be successful, we would elucidate a process that is currently poorly understood while potentially uncovering novel therapeutic avenues for the treatment of many genetic diseases and cancers.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406511
Name
Shen Leo L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Genetic Modifiers of Eukaryotic Translation Termination
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Crispr Screen; Genetic Screen; Nonsense Mutation; Nonsense Suppression; Positive Selection Assay; Readthrough Reporter; Readthrough Therapy; Stop Codon Readthrough; Suppressors Of Translation Termination; Translation Termination
Abstract
Genes function as instruction manuals for making proteins, encoding transcripts that are ultimately decoded to make proteins that perform a vast array of functions in our cells. During the translation of these transcripts, certain sequences (termed stop or termination codons) signal to the cell machinery that the full-length protein has been synthesized and it is time to stop. Sometimes, however, this process can be disrupted by mutations that introduce premature termination codons (PTCs), resulting in the synthesis of truncated proteins. These mutations have been linked to many genetic diseases, such as Duchenne muscular dystrophy, cystic fibrosis, and a plethora of cancer syndromes. Therefore, developing strategies to “mask” stop codon recognition and re-initiate production of full-length proteins in order to restore, at the very least, partial protein function could have significant therapeutic applications. In fact, certain drugs (eg. aminoglycosides) already do this and have been shown to reduce disease severity in cancer cells, but they only do so at very high concentrations that are eventually toxic. Another drug (Ataluren) that promotes readthrough of PTCs is already being used in Europe to treat Duchenne muscular dystrophy patients, demonstrating the feasibility of suppressing stop codons as a form of therapy. In this project, we hope to better understand the mechanisms behind translation termination and how fidelity is maintained. To achieve this, we will design genetic screens using CRISPR technology to find suppressors of translation termination. Should we be successful, we would elucidate a process that is currently poorly understood while potentially uncovering novel therapeutic avenues for the treatment of many genetic diseases and cancers.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shen, Leo L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~